The overarching goal of the HCCC Experimental Therapeutics (ET) program is to develop and test novel cancer therapeutics. To accomplish this, ET has three central research themes: 1) Therapeutic Targets and Lead Discovery, 2) Novel Drug Delivery Approaches and 3) Clinical Therapeutics. ET has 30 full members and 17 associate members. Members have appointments across 3 colleges (Medicine, Pharmacy and Liberal Arts and Sciences) and 11 departments. Many ET members contribute to more than one theme. Total peer- reviewed annual research funding to ET is $4.33 million ($2.44 from the NCI) with $10.44 million in funding for non-peer reviewed research projects. ET members are highly productive and collaborative. ET members have authored or co-authored 305 cancer-related publications since April 1, 2011 with 49% (n=148) addressing therapeutic targets and lead discovery, 14% (n=43) addressing novel drug delivery approaches and 36% (n=108) addressing clinical therapeutics. 19% (n=59) were intra-programmatic, 37% (n=113) inter- programmatic, and 30% (n=93) inter-institutional. 26 manuscripts were published in high impact journals (impact factor >10). In the Therapeutic Targets and Lead Discovery theme, groups of investigators collaborate based on experimental therapeutics geared towards specific pathways, as well as cancer types. In the Novel Drug Delivery Approaches theme, ET investigators are evaluating nanoparticles, aptamers and novel approaches to cancer immunotherapy for treating prostate cancer, lymphoma, melanoma and breast cancer. Investigators in the Clinical Therapeutics theme are exploring mechanisms of action of clinical therapeutics and participating in or leading 145 active clinical trials across a spectrum of cancer types as coordinated through the disease specific Multidisciplinary Oncology Groups (MOGs). As a program, an increasing focus of ET is to facilitate movement of promising molecularly-targeted therapeutic approaches through the developmental therapeutics pipeline.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-18
Application #
9460397
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
18
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Lee, Jennifer E; Anderson, Carryn M; Perkhounkova, Yelena et al. (2018) Transcutaneous Electrical Nerve Stimulation Reduces Resting Pain in Head and Neck Cancer Patients: A Randomized and Placebo-Controlled Double-Blind Pilot Study. Cancer Nurs :
McAtee, Caitlin O; Booth, Christine; Elowsky, Christian et al. (2018) Prostate tumor cell exosomes containing hyaluronidase Hyal1 stimulate prostate stromal cell motility by engagement of FAK-mediated integrin signaling. Matrix Biol :
Leelakanok, Nattawut; Geary, Sean M; Salem, Aliasger K (2018) Antitumor Efficacy and Toxicity of 5-Fluorouracil-Loaded Poly(Lactide Co-glycolide) Pellets. J Pharm Sci 107:690-697
Sperduto, Paul W; Deegan, Brian J; Li, Jing et al. (2018) Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. Int J Radiat Oncol Biol Phys 101:845-853
Nagaraja, Archana S; Dood, Robert L; Armaiz-Pena, Guillermo et al. (2018) Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 3:
Smith, Sonali M; Godfrey, James; Ahn, Kwang Woo et al. (2018) Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer 124:2541-2551
Abarca, Tyler; Gao, Yubo; Monga, Varun et al. (2018) Improved survival for extremity soft tissue sarcoma treated in high-volume facilities. J Surg Oncol 117:1479-1486
Brogden, Kim A; Parashar, Deepak; Hallier, Andrea R et al. (2018) Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer 18:225
Do, Anh-Vu; Worthington, Kristan S; Tucker, Budd A et al. (2018) Controlled drug delivery from 3D printed two-photon polymerized poly(ethylene glycol) dimethacrylate devices. Int J Pharm 552:217-224
O'Leary, Brianne R; Houwen, Frederick K; Johnson, Chase L et al. (2018) Pharmacological Ascorbate as an Adjuvant for Enhancing Radiation-Chemotherapy Responses in Gastric Adenocarcinoma. Radiat Res 189:456-465

Showing the most recent 10 out of 1080 publications